bulb
field
import
eye
catcher
netherland
besid
visibl
attract
larg
econom
import
reason
agricultur
scienc
tradit
flourish
netherland
includ
microbiolog
better
bacteriolog
studi
prevent
contagi
infect
plant
set
led
martinu
willem
beijerinck
discov
preval
mosaic
diseas
tobacco
time
import
crop
caus
filter
agent
call
contagium
vivum
fluidum
coin
term
viru
agent
known
tobacco
mosaic
viru
start
virolog
research
tradit
netherland
today
virolog
still
main
research
area
biolog
scienc
fundament
branch
dutch
gene
therapi
research
born
virolog
field
progress
made
gene
therapi
scientist
netherland
signific
impact
translat
gene
therapi
clinic
nation
intern
level
expertis
dutch
gene
therapi
scientist
also
recogn
intern
level
demonstr
fact
variou
dutch
research
group
particip
sever
preclin
clinicalori
european
gene
therapi
project
support
framework
programm
european
union
tabl
paper
present
brief
overview
mileston
dutch
basic
gene
therapi
research
well
past
present
futur
clinic
gene
therapi
trial
netherland
basic
gene
therapi
research
initi
lab
alex
van
der
eb
chose
adenovirus
research
model
adenovirus
first
identifi
row
colleagu
tri
establish
cell
line
adenoid
tissu
tonsil
transmiss
agent
found
respons
degener
cultur
serotyp
human
adenovirus
hadv
describ
date
classifi
six
speci
f
formerli
call
subgroup
evolut
classif
adenovirus
recent
review
adenovirus
attract
much
attent
discoveri
trentin
et
al
huebner
et
al
certain
serotyp
ie
serotyp
speci
induc
tumor
newborn
hamster
wherea
other
ie
serotyp
speci
c
weakli
oncogen
observ
trigger
van
der
eb
leiden
use
adenovirus
model
anim
studi
cellular
transform
vitro
tumor
induct
vivo
led
observ
differ
oncogen
correl
capac
downregul
antigen
present
mhc
class
illustr
import
immun
system
prevent
tumor
growth
adenovirus
play
import
role
fundament
biomed
research
provid
model
system
studi
organ
eukaryot
gene
regul
express
well
studi
mechan
dna
replic
mammalian
cell
latter
studi
perform
predominantli
lab
john
sussenbach
peter
van
der
vliet
utrecht
studi
led
detail
insight
mani
cellular
viral
process
also
yield
variou
broadli
applic
tool
techniqu
graham
van
der
eb
paper
describ
calcium
techniqu
effici
transfer
nake
adenoviru
dna
cultur
cell
cite
time
cheap
effici
techniqu
dna
transfer
routin
virtual
cell
biolog
laboratori
techniqu
use
frank
graham
alex
van
der
eb
lab
show
human
cell
transform
immort
nake
adenoviru
dna
exemplifi
cell
line
obtain
transform
embryon
kidney
cell
shear
adenoviru
dna
later
leiden
group
gener
cell
line
transfer
plasmid
carri
defin
adenoviru
type
sequenc
human
embryon
retinoblast
observ
adenovirustransform
cell
use
propag
virus
defect
earli
region
gene
facilit
develop
use
replicationdefect
adenoviru
vector
rel
easi
gener
replicationdefect
vector
made
vector
prime
choic
mani
gene
therapist
although
use
cell
line
intrins
problem
propag
replicationdefect
adenoviru
vector
replicationcompet
adenovirus
rca
gener
high
frequenc
rca
revert
vector
reacquir
region
lose
transgen
cassett
result
recombin
homolog
sequenc
integr
helper
cell
vector
backbon
attempt
solv
problem
leiden
group
collabor
scientist
introgen
crucel
gener
cell
line
line
establish
transfer
minim
portion
adenoviru
serotyp
genom
bp
human
embryon
retinoblast
use
calcium
techniqu
process
glp
condit
use
cell
line
vector
produc
extens
character
cell
system
use
product
clinicalgrad
adenovirusvector
batch
use
cell
line
combin
match
vector
sequenc
homolog
larg
solv
issu
rca
gener
homolog
recombin
also
scientist
field
embrac
gene
therapi
approach
work
phd
student
alex
van
der
eb
group
leiden
dinko
valerio
first
report
clone
human
adenosin
deaminas
ada
cdna
correspond
gene
embrac
retrovir
vector
technolog
eventu
use
vector
transfer
ada
cdna
hematopoiet
stem
cell
three
ada
patient
studi
perform
french
british
scientist
repres
first
studi
hematopoiet
stem
cell
ada
patient
modifi
addit
valerio
found
compani
introgen
call
crucel
crucel
one
key
player
adenoviralvector
field
pioneer
use
fibermodifi
adenoviru
serotyp
deriv
vector
overcom
pauciti
adenoviru
receptor
car
circumv
preexist
immun
respect
relat
retrovir
vector
cancer
studi
sever
lab
anton
bern
amsterdam
examin
murin
leukaemia
virus
mlv
induc
tumor
upon
infect
newborn
mice
recogn
retrovirus
found
tumor
often
integr
common
site
site
provirus
disturb
express
nearbi
gene
common
integr
site
point
associ
nearbi
gene
induct
leukem
state
bern
analys
common
integr
site
led
identif
sever
gene
involv
leukaemia
use
mlv
infect
transgen
anim
delin
pathway
virusinduc
leukaemia
relev
observ
gene
therapi
becam
appar
develop
leukaemia
four
infant
born
xlink
sever
combin
immunodefici
scid
gene
success
treat
infus
autolog
hematopoiet
stem
cell
transduc
defect
retrovir
vector
attribut
deregul
express
gene
integr
vector
proviru
amsterdam
use
adenoassoci
vector
aav
thoroughli
exploit
compani
amsterdam
molecular
therapeut
amt
found
gener
produc
stateoftheart
aav
clinic
studi
greatli
facilit
scientist
move
lab
clinic
oper
amt
boost
translat
gene
therapi
research
netherland
date
research
viral
vector
significantli
expand
netherland
variou
lab
rotterdam
amsterdam
groningen
leiden
explor
divers
target
strategi
increas
select
adenovirus
oncolyt
agent
transduct
target
studi
van
beusechem
collabor
replac
adenoviru
fiber
sequenc
spike
protein
reoviru
hoeben
collabor
develop
adenoviru
minor
capsid
protein
ix
anchor
target
ligand
transcript
target
vector
glioblastoma
cell
employ
sillevi
smitt
collabor
cholangiocarcinoma
cell
bosma
group
prostat
cancer
cell
kraaij
collabor
optim
deliveri
method
enhancedeffici
vector
evalu
cell
cultur
spheroid
cell
aggreg
tumor
explant
tissu
slice
smallanim
model
approach
limit
adenoviru
vector
also
rna
virus
reovirus
alphavirus
coronavirus
evalu
use
anticanc
strategi
kranenburg
collabor
link
capac
reoviru
induc
tumorcellspecif
cell
death
propens
reoviru
sensit
rastransform
cell
apoptosi
wilschut
pioneer
use
alphavirus
use
erad
preestablish
tumor
immun
protocol
collabor
project
rottier
gerritsen
group
redirect
mous
hepat
coronaviru
human
tumor
cell
use
monoclonalantibodi
depend
target
strategi
led
effici
syncytium
format
tumor
cell
may
eventu
enhanc
antitumor
effici
approach
addit
retrovir
vector
use
studi
aim
target
lymphocyt
tumor
studi
adopt
transfer
autolog
lymphocyt
genet
modifi
express
antigenspecif
receptor
may
provid
tumorspecif
immun
cancer
patient
approach
clinic
evalu
rotterdam
studi
initi
soon
amsterdam
leiden
utrecht
strategi
manag
graftversushost
diseas
donor
lymphocyt
infus
develop
sever
approach
brought
clinic
evalu
see
nijmegen
van
den
berg
collabor
develop
vector
modifi
express
gene
specif
respons
inflammatori
signal
finetun
gene
therapi
rheumatoid
arthriti
synthet
nonvir
vector
may
prefer
viral
vector
particular
gene
therapi
applic
new
vector
system
develop
groningen
use
socal
virosom
evalu
wilschut
collabor
virosom
viruslik
particl
consist
reconstitut
viru
envelop
lack
genet
materi
nativ
viru
studi
provid
insight
macromolecul
transfer
across
cytoplasm
membran
macromolecul
releas
endosom
cytoplasm
utrecht
hennink
collabor
explor
use
cation
polym
base
gene
deliveri
system
approach
twosid
one
hand
new
polym
gener
character
hand
cell
biolog
use
pinpoint
intracellular
process
tabl
limit
effici
gene
transfer
lambin
group
maastricht
take
radic
differ
approach
evalu
use
recombin
anaerob
clostridi
spore
highli
select
gene
deliveri
vector
ingenu
also
evid
recent
use
tattoo
devic
intraderm
dna
vaccin
dutch
cancer
institut
amsterdam
procedur
led
robust
cell
respons
erad
preestablish
subcutan
tumor
may
broadli
applic
overview
complet
ongo
futur
clinic
gene
therapi
trial
treatment
variou
diseas
netherland
present
tabl
total
trial
complet
tabl
trial
ongo
tabl
protocol
start
near
futur
tabl
dutch
scientist
front
line
field
clinic
gene
therapi
well
mention
earlier
first
clinic
trial
worldwid
treatment
patient
ada
defici
autolog
stem
cell
genet
modifi
retrovir
vector
conduct
collabor
dutch
french
british
scientist
susann
osanto
collabor
leiden
amongst
first
europ
treat
patient
cancer
genemodifi
allogen
melanoma
cell
express
high
level
furthermor
chri
bangma
rotterdam
perform
clinic
studi
adenovirusmedi
suicid
gene
therapi
prostat
cancer
outpati
basi
variou
gene
therapi
concept
develop
dutch
research
group
translat
clinic
exampl
rotterdam
trial
tabl
protocol
im
studi
lymphocyt
retarget
carbon
anhydras
ix
treatment
metastas
renal
cell
carcinoma
protein
overexpress
tumor
cell
addit
amsterdam
aavmedi
gene
therapi
patient
lipoprotein
lipas
defici
test
tabl
protocol
im
exon
skip
antisens
oligoribonucleotid
restor
dystrophin
product
duchenn
muscular
dystrophi
patient
clinic
evalu
leiden
tabl
protocol
id
dutch
clinic
gene
therapi
trial
phase
studi
aim
assess
safeti
tabl
trial
conduct
collabor
dutch
compani
amsterdam
molecular
therapeut
amsterdam
result
trial
confirm
gener
observ
gene
therapi
well
toler
without
major
complic
rotterdam
trial
lymphocyt
retarget
renal
cell
carcinoma
describ
tabl
protocol
im
liver
toxic
encount
first
three
patient
trial
allow
continu
accord
amend
protocol
two
patient
includ
without
side
effect
accord
trial
conduct
countri
clear
clinic
efficaci
gene
therapi
demonstr
yet
dutch
trial
two
random
placebocontrol
phase
iii
trial
gene
therapi
brain
tumor
tabl
protocol
im
critic
limb
ischemia
diabet
mellitu
efficaci
could
establish
clinic
effect
minor
first
result
report
leiden
trial
studi
suicid
gene
therapi
patient
loosen
hip
prosthesi
tabl
protocol
im
promis
trial
interfac
tissu
around
implant
destroy
suicid
gene
therapi
prior
fixat
prosthesi
cement
ongo
upcom
clinic
trial
focu
translat
new
develop
gene
therapi
research
aim
improv
efficaci
safeti
treatment
modal
first
dutch
trial
oncolyt
adenoviru
therapi
cancer
carri
amsterdam
rotterdam
tabl
furthermor
restor
genet
defect
scid
address
includ
genet
lipoprotein
lipas
defici
duchenn
muscular
dystrophi
leber
congenit
amaurosi
caus
blind
crigler
najjar
syndrom
caus
irrevers
brain
damag
due
hyperbilirubinemia
tabl
dutch
ministri
health
commit
gene
therapi
trial
approv
fund
translat
gene
therapi
research
programm
develop
execut
fund
agenc
zonmw
programm
aim
improv
translat
preclin
gene
therapi
research
clinic
wwwzonmwnlgenetherapi
far
phase
iii
trial
describ
tabl
support
programm
zonmw
stimul
cooper
research
commerci
enterpris
besid
investigatoriniti
clinic
studi
commerci
interest
clinic
gene
therapi
netherland
increas
phase
iii
clinic
studi
leiden
involv
suicid
gene
therapi
approach
prosthesi
refix
sponsor
innovata
ltd
ruddington
uk
current
amsterdam
molecular
therapeut
particip
amsterdam
trial
lipoprotein
lipas
defici
tabl
protocol
im
anoth
dutch
compani
prosensa
bv
base
leiden
involv
leiden
trial
duchenn
muscular
dystrophi
tabl
protocol
id
dutch
drug
develop
compani
orca
therapeut
bv
amsterdam
current
prepar
lead
product
oncolyt
adenovirusexpress
tumor
suppressor
clinic
evalu
cancer
patient
anoth
compani
arthrogen
bv
amsterdam
develop
aavbas
gene
therapi
rheumatoid
arthriti
futur
clinic
applic
furthermor
least
four
dutch
clinic
centr
particip
larg
phase
iii
intern
multicent
immunogen
therapi
trial
prostat
cancer
sponsor
cell
genesi
inc
san
fransisco
usa
tabl
protocol
im
dutch
scientist
involv
fundament
clinic
gene
therapi
research
significantli
contribut
progress
made
research
area
includ
translat
innov
develop
clinic
latter
process
greatli
stimul
translat
gene
therapi
research
programm
support
zonmw
mani
dutch
academ
research
center
made
longterm
commit
clinic
research
involv
gene
therapi
result
establish
variou
gene
transfer
facil
nation
regulatori
conundrum
precipit
establish
gene
therapi
offic
coordin
assess
clinic
protocol
variou
regulatori
bodi
aid
applic
warrant
effici
commun
amongst
pertin
regulatori
bodi
applic
see
paper
bleij
et
al
issu
atmospher
surround
dutch
gene
therapi
may
also
evid
fact
sever
activ
dutch
scientist
accept
invit
serv
review
panel
advisori
board
involv
regul
clinic
gene
therapi
also
dutch
societi
gene
therapi
formal
role
evalu
gene
therapi
offic
tight
network
interrel
ensur
effici
commun
dutch
gene
therapi
commun
bodi
facilit
safe
effici
progress
power
field
